Madrigal Pharmaceuticals reports significant sales growth amid market competition
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 18 2026
0mins
Source: NASDAQ.COM
Madrigal Pharmaceuticals Inc. saw its stock rise by 5.28% as it reached a 20-day high, despite the broader market decline with the Nasdaq-100 down 2.10% and the S&P 500 down 1.50%.
The company's impressive performance is attributed to a remarkable 432% increase in sales from its Rezdiffra drug in 2025, totaling $958.4 million. This growth positions Madrigal favorably against competitors like Summit Therapeutics, which faces FDA review risks for its ivonescimab drug. The competitive landscape in the biotech sector is intensifying, but Madrigal's strong sales figures indicate a solid market presence and potential for continued success.
As the biotech market evolves, Madrigal's ability to maintain its growth trajectory will be crucial. Investors are likely to keep a close eye on the company's upcoming developments and how it navigates the competitive pressures from other firms in the sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MDGL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MDGL
Wall Street analysts forecast MDGL stock price to rise
12 Analyst Rating
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 514.390
Low
527.00
Averages
636.22
High
900.00
Current: 514.390
Low
527.00
Averages
636.22
High
900.00
About MDGL
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ribo and Madrigal Achieve siRNA Drug Milestone
- Candidate Nomination Success: Suzhou Ribo Life Science and Madrigal Pharmaceuticals have successfully nominated their first drug candidate in their siRNA partnership, marking a significant milestone that is expected to expedite the IND application process for clinical studies.
- Focus on MASH Treatment: This collaboration targets metabolically driven steatohepatitis (MASH), an area with substantial unmet medical needs, and aims to develop innovative RNA therapeutics to address this condition.
- Complementary Technical Strengths: Ribo's expertise in siRNA drug research and delivery technology, combined with Madrigal's market leadership in MASH, has facilitated rapid project advancement, showcasing the synergistic effects of their collaboration in drug development.
- Global Patient Benefit: Both parties are committed to advancing the development of novel siRNA candidates, aiming to provide new treatment options for MASH patients worldwide, reflecting their dedication to addressing significant health challenges.
See More
Ribo Life Science and Madrigal Achieve Key Collaboration Milestone
- Candidate Drug Nomination: Suzhou Ribo Life Science and Madrigal Pharmaceuticals have successfully achieved a candidate drug nomination milestone in their siRNA collaboration, highlighting their joint commitment to advancing therapies for metabolic-associated liver diseases.
- Clinical Research Preparation: This milestone will facilitate the immediate initiation of preclinical studies necessary for the clinical trial application, expected to provide new treatment options for global MASH patients, addressing significant unmet medical needs.
- Complementary Technical Strengths: Ribo's leading capabilities in siRNA drug discovery and delivery technology, combined with Madrigal's clinical expertise in MASH, create a robust foundation for collaboration, accelerating project progress.
- Global Market Potential: This partnership not only expands the therapeutic landscape for MASH but also demonstrates both parties' determination to drive innovative therapies globally, aiming to deliver more effective treatment solutions for patients.
See More
Ribo Life Science and Madrigal Advance Drug Development Collaboration
- Collaboration Milestone: Suzhou Ribo Life Science and Madrigal Pharmaceuticals have successfully designated their first drug candidate, marking a significant advancement in their partnership focused on RNA interference therapies, which is expected to accelerate the initiation of new drug research to meet urgent liver disease treatment needs.
- Clinical Trial Preparation: This collaboration will immediately launch new drug studies aimed at supporting upcoming clinical trials, particularly targeting metabolic dysfunction-associated steatohepatitis (MASH), addressing the unmet medical needs in this area.
- Complementary Technical Strengths: Ribo's world-class capabilities in RNA interference drug discovery and delivery technology, combined with Madrigal's extensive clinical expertise in MASH, enable rapid project advancement, enhancing the efficiency of new therapy development.
- Significant Market Potential: As the number of MASH patients rises, this partnership not only aids in developing innovative therapies but also has the potential to provide new treatment options for patients worldwide, further solidifying both companies' market positions in the biopharmaceutical sector.
See More
Ribo and Madrigal Achieve siRNA Drug Milestone
- Milestone Achievement: Suzhou Ribo Life Science and Madrigal Pharmaceuticals have successfully reached the first candidate drug nomination milestone in their siRNA partnership, indicating efficient collaboration in liver disease treatment, with immediate initiation of IND-enabling studies to support clinical research.
- Focus on MASH: This collaboration targets metabolic dysfunction-associated steatohepatitis (MASH), a field with significant unmet medical needs, and the joint efforts are expected to broaden therapeutic options for this condition, enhancing patient quality of life.
- Complementary Strengths: Ribo's world-class capabilities in siRNA drug discovery and delivery technology, combined with Madrigal's market-leading clinical expertise in MASH, have accelerated project progress, highlighting the strategic importance of their partnership.
- Commitment to Global Development: Ribo and its subsidiary Ribocure are dedicated to the global development of life-saving oligonucleotide therapies, leveraging innovative R&D capabilities to address real medical needs worldwide and advance clinical trials.
See More
Ribo Life Science and Madrigal Achieve Drug Candidate Milestone
- Milestone Achievement: Suzhou Ribo Life Science and Madrigal Pharmaceuticals have successfully reached the first drug candidate nomination milestone in their siRNA partnership, indicating rapid progress in liver disease treatment and paving the way for the initiation of IND-enabling studies to accelerate clinical trials.
- Complementary Strengths: Ribo's world-class capabilities in siRNA drug discovery and delivery technology, combined with Madrigal's market-leading clinical expertise in metabolic dysfunction-associated steatohepatitis (MASH), will expedite the development of novel therapies for this condition.
- Significant Market Need: The collaboration addresses the tremendous unmet medical need in the MASH field, broadening the potential for liver-directed therapeutics and offering new treatment options for patients worldwide, reflecting both companies' commitment to innovative drug development.
- Global Development Strategy: Ribo Life Science and its subsidiary Ribocure are dedicated to the global development of life-saving oligonucleotide therapies, leveraging a strong product pipeline and innovative capabilities to tackle serious diseases and successfully conduct clinical trials.
See More
Ribo Life Science and Madrigal Achieve Drug Candidate Milestone
- Drug Candidate Milestone: Suzhou Ribo Life Science and Madrigal Pharmaceuticals have successfully achieved the first candidate drug nomination milestone, indicating efficient collaboration in their siRNA partnership, with immediate plans to initiate IND-enabling studies to support clinical research.
- Focus on Liver Disease: This collaboration targets metabolic dysfunction-associated steatohepatitis (MASH), a field with significant unmet medical needs, and aims to enhance treatment options for patients suffering from this condition.
- Complementary Technical Strengths: Ribo possesses world-class capabilities in siRNA drug discovery and delivery technology, while Madrigal has established a market-leading presence and profound clinical expertise in the MASH field, with their combined strengths accelerating project progress.
- Global Development Strategy: Ribo and its subsidiary Ribocure are dedicated to the global development of life-saving oligonucleotide therapies, aiming to leverage innovative capabilities and clinical trials to advance siRNA drug development and address real unmet medical needs worldwide.
See More
Ribo and Madrigal Achieve siRNA Drug Milestone
- Candidate Nomination Success: Suzhou Ribo Life Science and Madrigal Pharmaceuticals have successfully nominated their first drug candidate in their siRNA partnership, marking a significant milestone that is expected to expedite the IND application process for clinical studies.
- Focus on MASH Treatment: This collaboration targets metabolically driven steatohepatitis (MASH), an area with substantial unmet medical needs, and aims to develop innovative RNA therapeutics to address this condition.
- Complementary Technical Strengths: Ribo's expertise in siRNA drug research and delivery technology, combined with Madrigal's market leadership in MASH, has facilitated rapid project advancement, showcasing the synergistic effects of their collaboration in drug development.
- Global Patient Benefit: Both parties are committed to advancing the development of novel siRNA candidates, aiming to provide new treatment options for MASH patients worldwide, reflecting their dedication to addressing significant health challenges.
See More
Ribo Life Science and Madrigal Achieve Key Collaboration Milestone
- Candidate Drug Nomination: Suzhou Ribo Life Science and Madrigal Pharmaceuticals have successfully achieved a candidate drug nomination milestone in their siRNA collaboration, highlighting their joint commitment to advancing therapies for metabolic-associated liver diseases.
- Clinical Research Preparation: This milestone will facilitate the immediate initiation of preclinical studies necessary for the clinical trial application, expected to provide new treatment options for global MASH patients, addressing significant unmet medical needs.
- Complementary Technical Strengths: Ribo's leading capabilities in siRNA drug discovery and delivery technology, combined with Madrigal's clinical expertise in MASH, create a robust foundation for collaboration, accelerating project progress.
- Global Market Potential: This partnership not only expands the therapeutic landscape for MASH but also demonstrates both parties' determination to drive innovative therapies globally, aiming to deliver more effective treatment solutions for patients.
See More
Ribo Life Science and Madrigal Advance Drug Development Collaboration
- Collaboration Milestone: Suzhou Ribo Life Science and Madrigal Pharmaceuticals have successfully designated their first drug candidate, marking a significant advancement in their partnership focused on RNA interference therapies, which is expected to accelerate the initiation of new drug research to meet urgent liver disease treatment needs.
- Clinical Trial Preparation: This collaboration will immediately launch new drug studies aimed at supporting upcoming clinical trials, particularly targeting metabolic dysfunction-associated steatohepatitis (MASH), addressing the unmet medical needs in this area.
- Complementary Technical Strengths: Ribo's world-class capabilities in RNA interference drug discovery and delivery technology, combined with Madrigal's extensive clinical expertise in MASH, enable rapid project advancement, enhancing the efficiency of new therapy development.
- Significant Market Potential: As the number of MASH patients rises, this partnership not only aids in developing innovative therapies but also has the potential to provide new treatment options for patients worldwide, further solidifying both companies' market positions in the biopharmaceutical sector.
See More
Ribo and Madrigal Achieve siRNA Drug Milestone
- Milestone Achievement: Suzhou Ribo Life Science and Madrigal Pharmaceuticals have successfully reached the first candidate drug nomination milestone in their siRNA partnership, indicating efficient collaboration in liver disease treatment, with immediate initiation of IND-enabling studies to support clinical research.
- Focus on MASH: This collaboration targets metabolic dysfunction-associated steatohepatitis (MASH), a field with significant unmet medical needs, and the joint efforts are expected to broaden therapeutic options for this condition, enhancing patient quality of life.
- Complementary Strengths: Ribo's world-class capabilities in siRNA drug discovery and delivery technology, combined with Madrigal's market-leading clinical expertise in MASH, have accelerated project progress, highlighting the strategic importance of their partnership.
- Commitment to Global Development: Ribo and its subsidiary Ribocure are dedicated to the global development of life-saving oligonucleotide therapies, leveraging innovative R&D capabilities to address real medical needs worldwide and advance clinical trials.
See More
Ribo Life Science and Madrigal Achieve Drug Candidate Milestone
- Milestone Achievement: Suzhou Ribo Life Science and Madrigal Pharmaceuticals have successfully reached the first drug candidate nomination milestone in their siRNA partnership, indicating rapid progress in liver disease treatment and paving the way for the initiation of IND-enabling studies to accelerate clinical trials.
- Complementary Strengths: Ribo's world-class capabilities in siRNA drug discovery and delivery technology, combined with Madrigal's market-leading clinical expertise in metabolic dysfunction-associated steatohepatitis (MASH), will expedite the development of novel therapies for this condition.
- Significant Market Need: The collaboration addresses the tremendous unmet medical need in the MASH field, broadening the potential for liver-directed therapeutics and offering new treatment options for patients worldwide, reflecting both companies' commitment to innovative drug development.
- Global Development Strategy: Ribo Life Science and its subsidiary Ribocure are dedicated to the global development of life-saving oligonucleotide therapies, leveraging a strong product pipeline and innovative capabilities to tackle serious diseases and successfully conduct clinical trials.
See More
Ribo Life Science and Madrigal Achieve Drug Candidate Milestone
- Drug Candidate Milestone: Suzhou Ribo Life Science and Madrigal Pharmaceuticals have successfully achieved the first candidate drug nomination milestone, indicating efficient collaboration in their siRNA partnership, with immediate plans to initiate IND-enabling studies to support clinical research.
- Focus on Liver Disease: This collaboration targets metabolic dysfunction-associated steatohepatitis (MASH), a field with significant unmet medical needs, and aims to enhance treatment options for patients suffering from this condition.
- Complementary Technical Strengths: Ribo possesses world-class capabilities in siRNA drug discovery and delivery technology, while Madrigal has established a market-leading presence and profound clinical expertise in the MASH field, with their combined strengths accelerating project progress.
- Global Development Strategy: Ribo and its subsidiary Ribocure are dedicated to the global development of life-saving oligonucleotide therapies, aiming to leverage innovative capabilities and clinical trials to advance siRNA drug development and address real unmet medical needs worldwide.
See More
